SCHEMBL2216183

SCHEMBL2216183

O=C(Nc1ccc(Nc2nc(-c3cccc4c3oc3ccccc34)cc3ccnn23)cc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.38
DNMT1 P26358 2/20 0.36
DNMT3A Q9Y6K1 2/20 0.36
PABPC1 P11940 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
POLB P06746 2/20 0.36
AURKA O14965 1/20 0.36
MAPK13 O15264 1/20 0.36
CHEK2 O96017 1/20 0.36
NTRK1 P04629 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215080 0.95 LMNA (0.50) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2215221 0.93 MAPT (0.42) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2214233 0.93 DNMT1 (0.42) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2213218 0.92 TRPV1 (0.42) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2214178 0.92 KDM4E (0.39) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL2215243 0.91 HSD17B10 (0.38) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2212315 0.91 MAPT (0.41) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2215134 0.90 LOXL2 (0.38) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2215529 0.90 ALDH1A1 (0.38) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD
SCHEMBL2215322 0.90 KDM4E (0.37) ALDH1A1KDM4EHSD17B10SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 ALDH1A1 1334/4885KDM4E 3784/4885HSD17B10 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.